SWAN-PSMA-1007 1 ml / 10 ml, Injektionslösung

7680673700013 CH-67370 Injektionslösung
SWAN-PSMA-1007 1 ml / 10 ml, Injektionslösung
SWAN-PSMA-1007 1 ml / 10 ml, Injektionslösung
SWAN-PSMA-1007 1 ml / 10 ml, Injektionslösung
1 / 3
google

Article details

Package size
15 mL
Selling units
15
Measure
Durchstechflasche(n)
Galenic form
Injektionslösung
Galenic group
Injektion/Infusion

Official Swissmedic V2 data

Additional information from the official database

Official medical documents

Summary of Product Characteristics
Allemand
23/01/2025
Summary of Product Characteristics
Français
23/01/2025
Summary of Product Characteristics
Italien
23/01/2025

Detailed composition

Substance Quantity Type Category
(18F)-PSMA-1007
222.0 MBQ Substance Wirkstoff (Principe actif)
dinatrii phosphas
- Substance HNIDK
kalii dihydrogenophosphas
- Substance HNIDK
natrii chloridum
- Substance HNIDK
kalii chloridum
- Substance HNIDK
ethanolum
0.075 ML Substance HNIDK
ethanolum
60.0 MG Substance HBESI
natrii ascorbas
- Substance HNIDK
aqua ad iniectabile
- Substance HNIDK
natrium
4.6 MG Substance HBESI

Authorization holder

SWAN Isotopen AG

3010 Bern

Authorization information

Swissmedic authorization number
67370
Drug name
SWAN-PSMA-1007, Injektionslösung
Galenic form
LSINJ
ATC Code
V09IX17
Authorization status
Z
Dispensing category
A
First authorization
11/06/2024
Authorization expiration date
10/06/2029
IT Number
17.01.9.
Domain
Human medicine
Field of application
PET-Diagnose von PSMA-positivem Prostatakrebs

Package details

Description (FR)
SWAN PSMA 1007 1 ml / 10 ml sol inj 222 MBq 15mL p
Description (DE)
SWAN PSMA 1007 1 ml / 10 ml Inj Lös 222 MBq 15mL S
Market launch
11/06/2024
Narcotic (BTM)
No
Buy us a coffee Explore the data